- Inovio Pharmaceuticals (NASDAQ:INO) acquires the global (ex-China) rights to therapies for Alzheimer's disease and multiple sclerosis based on the work of DNA researcher Dr. Ben Wang from Fudan University's Shanghai Medical College.
- The therapies work by generating inducible regulatory T cells (iTreg). The cells are involved in shutting down immune responses after they have successfully eliminated invading organisms. They have potential in preventing autoimmune and inflammatory diseases.
- No financial terms are disclosed.
Inovio acquires rights to early stage therapies
Recommended For You
About INO Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
INO | - | - |
Inovio Pharmaceuticals, Inc. |